OncoMatch/Clinical Trials/NCT06662227
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Is NCT06662227 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Single dose and MMF Immunosuppression for b cell lymphoma.
Treatment: Single dose · MMF Immunosuppression — This study is a single-arm, single-center, investigator-initiated clinical trial. The primary objective is to evaluate the safety and preliminary efficacy of administering universal CD19 CAR-T cells to subjects with refractory and relapsed B-cell tumors. Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of universal UWD-19 to assess its safety and efficacy. Subjects will be hospitalized for a period, and after discharge, they will undergo periodic efficacy assessments and long-term survival follow-up for at least five years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positivity
CD19 positivity confirmed by flow cytometry or immunohistochemistry
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: second-line or higher treatment
Received ≥2 cycles of standardized second-line or higher treatment, and meets Lugano 2014 criteria for best clinical response: Progressive Disease (PD) on the most recent treatment. Stable Disease (SD) lasting <6 months before progressing.
Must have received: autologous stem cell transplant
Recurrence or progression ≤12 months post-autologous stem cell transplant
Cannot have received: targeted, epigenetic, or experimental drug therapy
Targeted, epigenetic, or experimental drug therapy within 14 days or 5 half-lives
Cannot have received: cytotoxic therapy
Cytotoxic therapy within 14 days
Cannot have received: immunomodulator
Immunomodulators within 7 days
Cannot have received: monoclonal antibody
Monoclonal antibodies within 21 days
Cannot have received: radiotherapy
Radiotherapy within 14 days
Lab requirements
Blood counts
Serum albumin ≥25 g/L; Oxygen saturation ≥95%; Blood transfusions allowed to maintain hemoglobin ≥8.0 g/dL; PT and APTT <2× ULN
Kidney function
Creatinine clearance ≥30 mL/min/1.73 m²
Liver function
ALT and AST ≤3.0× ULN; Total bilirubin ≤2.0× ULN (exceptions for congenital hyperbilirubinemia like Gilbert syndrome with direct bilirubin ≤1.5× ULN)
Cardiac function
No severe cardiac dysfunction (e.g., arrhythmias, unstable angina, recent MI, heart failure NYHA III/IV, uncontrolled hypertension)
Laboratory values indicating adequate organ and marrow function, with no severe cardiac, pulmonary, hepatic, renal, or immune dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify